What Is Liraglutide?

1. What Is Liraglutide?

Liraglutide is an active ingredient used in prescription GLP-1 receptor agonist medicines. The current DailyMed Victoza label and DailyMed Saxenda label both identify their products as liraglutide injections and as glucagon-like peptide-1, or GLP-1, receptor agonists.

That makes liraglutide a useful teaching example. It sits at the intersection of molecule names, brand names, label purposes, dosing-frequency shorthand, and GLP-1 history. The word “liraglutide” tells you the active ingredient. It does not, by itself, tell you whether someone is talking about Victoza, Saxenda, a generic product, a diabetes label, a weight-management label, or a specific product record.

The clean naming stack looks like this:

The most important habit is to keep those layers separate.

2. Why Liraglutide Matters in GLP-1 History

Liraglutide matters because it is older, once-daily, and still helps explain how GLP-1 naming evolved. FDA’s Victoza information page describes Victoza, liraglutide, as approved for adults with type 2 diabetes, and FDA’s December 2024 generic announcement described a first generic referencing Victoza as a once-daily GLP-1 injection for type 2 diabetes.

That history matters because today’s GLP-1 search language is often shaped by newer products. People hear “GLP-1” and may think of weekly semaglutide injections, tirzepatide brand names, oral semaglutide tablets, or weight-management headlines. Liraglutide is a reminder that the category did not start as one product, one schedule, or one use.

For broader category background, see What Is a GLP-1?. The short version is that GLP-1 receptor agonist is a class phrase. It does not erase differences between active ingredients, labels, routes, brand names, or product generations.

Liraglutide also makes the brand-versus-molecule distinction easier to see. “Victoza” and “Saxenda” are not just two spellings for the same public idea. They are different brand contexts for liraglutide, with different label framing and different reader expectations.

3. How Is Liraglutide Related to Victoza?

Victoza is a brand context for liraglutide. The current DailyMed Victoza label describes Victoza as a GLP-1 receptor agonist indicated for glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes mellitus, and it also includes cardiovascular-risk language for defined adults with type 2 diabetes and established cardiovascular disease.

FDA’s liraglutide marketed as Victoza information page places Victoza in the type 2 diabetes context. FDA’s December 23, 2024 generic announcement later described approval of the first generic referencing Victoza, also in a type 2 diabetes context.

That source pattern supports a careful public sentence: Victoza is a liraglutide brand associated with type 2 diabetes labeling. It does not support turning this article into product-selection advice, insurance advice, availability advice, or a claim that every liraglutide product has the same role.

The generic detail is worth mentioning because it marks liraglutide’s age in the GLP-1 timeline. FDA described the generic as referencing Victoza, not Saxenda. That distinction matters: generic status, brand reference, and label context are specific facts, not general market slogans.

4. How Is Liraglutide Related to Saxenda?

Saxenda is another brand context for liraglutide. The current DailyMed Saxenda label describes Saxenda as a GLP-1 receptor agonist indicated with reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in defined adult and pediatric populations.

That does not make Saxenda the same public object as Victoza. Both involve liraglutide. Both are injections. Both sit inside GLP-1 receptor agonist labeling. But their brand names point to different label contexts and different public conversations.

This is where molecule-first explanations become useful. If a note says “liraglutide,” it may be chemically accurate but still incomplete. If it says “Saxenda,” it adds a brand context. If it says “Saxenda liraglutide injection,” it is clearer. If it also records the source checked, such as a current DailyMed label, it becomes easier to separate verified label facts from memory.

This page does not summarize how Saxenda is used, how it is started, how doses change, or how anyone should respond to an adverse effect. Those are medical and label-administration questions, not the purpose of this explainer.

5. Why Once-Daily Wording Gets Attention

Once-daily wording gets attention because newer GLP-1 discussions often center on weekly injections or oral tablet developments. Current Victoza and Saxenda labels describe once-daily subcutaneous injection products, which makes liraglutide different at the label level from once-weekly injection labels for products such as Ozempic, Wegovy, Trulicity, Mounjaro, and Zepbound.

That difference is descriptive, not a ranking. A daily label is not automatically better, worse, older in a bad way, or easier to compare across products. It is one recordkeeping field among several: active ingredient, brand, route, frequency wording, label context, source, and date checked.

The frequency contrast is still useful because it prevents fuzzy statements like “GLP-1 shots are weekly.” Some are. Liraglutide is the common counterexample. A more careful educational sentence is: GLP-1 receptor agonist products can differ by active ingredient, brand, route, and labeled frequency.

For semaglutide-specific context, see What Is Semaglutide?. For brand-specific semaglutide explainers, see What Is Ozempic? and What Is Wegovy?.

6. Liraglutide, Semaglutide, Dulaglutide, and Tirzepatide

Liraglutide, semaglutide, dulaglutide, and tirzepatide are different active ingredients, not interchangeable spellings. Current labels describe liraglutide, semaglutide, and dulaglutide products as GLP-1 receptor agonists. Current tirzepatide labels describe tirzepatide as both a GIP receptor and GLP-1 receptor agonist.

The naming comparison is easiest in a table:

This table is a naming map, not an outcomes or safety comparison. Strength, tolerability, appropriateness, and ease of use require defined product labels, study populations, and clinical context that the table does not contain.

The table does answer a search problem: names that often appear together are not the same kind of name. Liraglutide, semaglutide, dulaglutide, and tirzepatide are molecule names. Victoza, Saxenda, Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound are brand contexts. GLP-1 receptor agonist and GIP/GLP-1 receptor agonist are category or mechanism phrases.

7. Generic Liraglutide Context

FDA announced on December 23, 2024, that it approved the first generic referencing Victoza, liraglutide injection, 18 mg/3 mL, for type 2 diabetes. That is a specific generic fact tied to Victoza-referenced liraglutide injection, not a broad statement about every brand use of liraglutide.

Generic context can be confusing because people often use “generic liraglutide” as if it answers every availability, cost, substitution, or brand question. It does not. FDA approval history, current product availability, pharmacy substitution rules, insurance coverage, and prescribing details are separate issues.

For an educational page, the reliable point is narrower: liraglutide is old enough in the U.S. GLP-1 landscape that FDA has announced a first generic referencing Victoza. That makes it different from newer active ingredients that may still be discussed mostly through brand names and current-label changes.

The clean generic point is narrow: FDA announced a Victoza-referenced liraglutide generic. That fact does not answer Saxenda questions, coverage questions, pharmacy substitution rules, or brand-to-generic switching questions.

8. Sources

9. What Is Liraglutide FAQ

• What is liraglutide in simple terms?

  Liraglutide is an active ingredient used in prescription GLP-1 receptor agonist medicines. Current U.S. label sources connect liraglutide with Victoza for type 2 diabetes and Saxenda for chronic weight-management contexts.

• Is liraglutide the same as Victoza or Saxenda?

  No. Liraglutide is the active ingredient. Victoza and Saxenda are brand names with different label contexts. Victoza is associated with type 2 diabetes labeling, while Saxenda is associated with chronic weight management labeling.

• Is liraglutide a daily or weekly GLP-1 medicine?

  Current Victoza and Saxenda labels describe once-daily subcutaneous injection products. That frequency makes liraglutide different at the label level from once-weekly GLP-1 products such as some semaglutide and dulaglutide injections.

• How is liraglutide different from semaglutide, dulaglutide, or tirzepatide?

  They are different active ingredients and brand families. Liraglutide is associated with Victoza and Saxenda, semaglutide with products such as Ozempic and Wegovy, dulaglutide with Trulicity, and tirzepatide with Mounjaro and Zepbound. Tirzepatide labels also include GIP receptor language.